Business Wire

CT-TERRA-TECHNOLOGY

9.12.2014 14:01:06 CET | Business Wire | Pressemeddelelse

Del
2014 Forecasting Benchmark Study Reveals Increased Complexity Limits Demand Planning Performance

The newly published 2014 Terra Technology Forecasting Benchmark Study finds that “growth through innovation” strategies continue to drive supply chain complexity at a rapid pace, making it harder for businesses to forecast. Data shows that demand planning has reached a performance ceiling with forecast value-added declining for a second year.

Terra’s fifth annual study analyzes demand planning performance for 13 multinational consumer products companies. It encompasses almost $200 billion in annual sales from North American and European businesses, with seven billion cases and 800,000 item-location combinations.

“It’s an exciting time in supply chain and I think we are close to a technology revolution. While driverless cars and drone deliveries are getting much of the press coverage, supply chain planning is finally starting to evolve,” says Robert F. Byrne, CEO of Terra Technology. “The steady stream of new product introductions combined with economic volatility and changing consumer preferences renders traditional forecasting methods obsolete. Our study confirms demand sensing as an enabling technology to break through the demand planning performance ceiling.”

Key findings for North America include:

  • Network complexity continues to increase at a rapid pace. The number of items for sale has increased by 30% since 2009. During the same period, shipments have grown by 2% causing average sales per item to fall by 22%.
  • The rate of new product introductions is considerably higher, with more than twice as many new items introduced over five years as existed in 2009; 85% of those have been discontinued.
  • Forecast value-added trends downwards again, losing 1% for an average of 12%; value-added measures the impact of demand planning efforts to improve a naïve statistical forecast.
  • The long tail continues to be a challenge for consumer products companies with the slowest-moving 50% of items contributing only 1% of sales while the fastest-moving 10% of items generate 75%.
  • Demand Planning is essentially stuck, with error hovering around 50% mark since the beginning of the study.
  • Demand Sensing provides a step-change in performance, cutting average forecast error by 38% across all items encompassed in the study and by 34% for new products.

The distinct regional requirements in Europe require more complex supply chains. Average sales volume per item was 2 times lower than in America, resulting in higher bias and forecast error.

This year’s study has been expanded to include findings on productivity. Participants unanimously report that planners spend too much time on mundane number-crunching tasks when that time should really be invested in more strategic activities. So it comes as no surprise that of the companies with higher than average forecast value-added, 65% have lighter workloads in terms of the number of products assigned to each full-time demand planner.

“We are thrilled that our customers find the study so valuable,” says Byrne. “The study’s insights allow member companies to compare their planning performance to peers and between business units, brands or even specific items within their organization. This has resulted in a number of tangible initiatives at member companies to reduce supply chain complexity, improve service and lower costs.”

The public version of the benchmark report captures the state of demand planning performance in North America, allowing readers to compare their forecast performance against the industry average and top performing companies. Terra publishes this information to contribute to the advancement of supply chain planning and encourage the pursuit of forecast excellence across all industries.

Request your copy  of Terra’s Forecasting Benchmark Study.

About Terra Technology

Terra Technology uses better mathematics to sense demand, optimize inventory and predict transportation and warehousing requirements for some of the world’s best-known companies including Shell, Procter & Gamble, Unilever, Mondelēz International, Kimberly-Clark, AkzoNobel, Kraft Foods, General Mills, ConAgra Foods, Kellogg, Campbell Soup and others. Terra invented demand sensing in 2002 and offered the first solutions to use retailer data systematically to improve supply chain efficiency, enhance service, cut inventory and reduce waste. Terra’s solutions are used in more than 160 countries. Information on how Terra enables a truly integrated supply chain can be found at terratechnology.com .

Contact:

PAN Communications
Maribel Lopez, +1 617 502 4339
PAN-Terra@pancomm.com
or
Terra Technology
John Lash, +1 203-847-4007 x112
john.lash@terratechnology.com

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye